Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Addiction: the clinical interface.

D Nutt1, A Lingford-Hughes

  • 1Psychopharmacology Unit, University of Bristol, Bristol, UK. David.J.Nutt@bristol.ac.uk

British Journal of Pharmacology
|April 17, 2008
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Approach-avoidance biases to self-harm cues in young people with self-harm.

Journal of affective disorders·2023
Same author

The blind men and the elephant: Systematic review of systematic reviews of cannabis use related health harms.

European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology·2020
Same author

Interdisciplinary working in public health research: a proposed good practice checklist.

Journal of public health (Oxford, England)·2017
Same author

Neural substrates of cue reactivity and craving in gambling disorder.

Translational psychiatry·2017
Same author

BAP guidelines on the management of weight gain, metabolic disturbances and cardiovascular risk associated with psychosis and antipsychotic drug treatment.

Journal of psychopharmacology (Oxford, England)·2016
Same author

Homological scaffolds of brain functional networks.

Journal of the Royal Society, Interface·2014
Same journal

Ursodeoxycholic acid inhibits platelet activation and thrombosis via TREM2: Evidence from mouse models and human studies.

British journal of pharmacology·2026
Same journal

Peripheral κ opioid receptor in pain and inflammation: From molecular signalling and gene expression to drug discovery.

British journal of pharmacology·2026
Same journal

Targeting KRAS for cancer therapy.

British journal of pharmacology·2026
Same journal

Fangchinoline alleviates hypertensive heart failure via PGC-1α/STAT6/PPARγ activation of mitophagy against ferroptosis.

British journal of pharmacology·2026
Same journal

The selective degradation of PDE4B shortform, using a PROTAC, leads to inhibition of several hallmarks of cancer in HCT116 cells.

British journal of pharmacology·2026
Same journal

Immune checkpoint inhibitor-induced arrhythmias: Mechanistic insights from clinical and preclinical studies.

British journal of pharmacology·2026
See all related articles

This review explores human pharmacology of addiction treatments, detailing opioid addiction therapies and the roles of dopamine and GABA-A systems. It highlights future research needs and drug development opportunities for addiction.

Area of Science:

  • Neuropharmacology
  • Addiction Medicine
  • Translational Pharmacology

Background:

  • Addiction is a complex brain disorder with significant public health implications.
  • Current treatments for addiction face challenges in efficacy and patient compliance.
  • Understanding the neurobiological underpinnings of addiction is crucial for developing effective therapies.

Purpose of the Study:

  • To provide a comprehensive overview of key issues in the human pharmacology of drugs of addiction.
  • To review the efficacy and mechanisms of current addiction treatments.
  • To identify areas for future research and drug development in addiction.

Main Methods:

  • Review of existing scientific literature on human pharmacology of addiction.
  • Analysis of evidence for treatment efficacy and mechanisms of action.

Related Experiment Videos

  • Examination of preclinical and clinical studies on neuropharmacological targets.

    • Main Results:

    • Detailed discussion of agonist, partial agonist, and antagonist treatments for opioid addiction.
    • Exploration of the roles of dopamine and GABA-A systems in drug dependence.
    • Consideration of dynamic and kinetic factors in addiction and treatment.

    Conclusions:

    • Further research is needed to optimize addiction treatments and improve patient compliance.
    • Novel preclinical targets show promise for future drug development in addiction.
    • A deeper understanding of neuropharmacology is essential for advancing addiction medicine.